CN109260188A - A kind of p-Coumaric Acid treats the purposes of people's acute lymphoblastic leukemia drug in preparation - Google Patents
A kind of p-Coumaric Acid treats the purposes of people's acute lymphoblastic leukemia drug in preparation Download PDFInfo
- Publication number
- CN109260188A CN109260188A CN201811515930.5A CN201811515930A CN109260188A CN 109260188 A CN109260188 A CN 109260188A CN 201811515930 A CN201811515930 A CN 201811515930A CN 109260188 A CN109260188 A CN 109260188A
- Authority
- CN
- China
- Prior art keywords
- coumaric acid
- purposes
- preparation
- acute lymphoblastic
- lymphoblastic leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to pharmaceutical technology field, a kind of p-Coumaric Acid is specifically related in the purposes of preparation treatment people's acute lymphoblastic leukemia drug, this drug has toxicity low, and Small side effects, selectivity is high, the advantages such as cheap.
Description
Technical field
The invention belongs to pharmaceutical technology fields, and it is thin in preparation treatment people's acute lymphoblastic to be specifically related to a kind of p-Coumaric Acid
The purposes of born of the same parents' leukemia medicament.
Background technique
P-Coumaric Acid (p-coumalic acid) chemical name is p- hydroxycinnamic acid, is mainly distributed on gramineae plant
Stem in.Hydroxycinnamic acid forms dimer by oxidation cross-linked reaction or participates in the synthetic reaction of lignin, keeps plant thin
Cell wall is in cross-linked state.This crosslinking is for maintaining the complete of plant cell wall and protection cell tissue from the micro- of invasion
Biological decomposition plays a significant role.
The main function of coumaric acid has:
1) antioxidant activity, p-Coumaric Acid have good antioxidant activity, to hydrogen peroxide, superoxide radical, it is light from
There is strong scavenging effect by base, peroxynitrite, has quenching effect to singlet oxygen.It is right while free radical is quenched
Coumaric acid can also inhibit the enzyme of free radical, promote to generate the enzyme for removing free radical.
2) antibacterial activity, to four kinds of different bacterial strains such as staphylococcus aureus, minimum inhibitory concentration (MIC) is
250 mcg/mls are also effective to hay bacillus etc..Bodini et al. further study show that, p-Coumaric Acid can adequately inhibit
Chromobacterium violaceum 5999 (Chromobacterium violaceum 5999), Agrobacterium NTL4
The group of (Agrobacteriumtumefaciens NTL4) and Pseudomonas chlororaphis (Pseudomonas chlororaphis)
(QuorumSensing) effect is incuded, to reach fungistatic effect.
3) antimutagenic activity, studies have shown that p-Coumaric Acid is for bleomycin (bleomycin), hydrogen peroxide and IQ type
The mutant salmonella that caye beautiful jade mutagen is induced has good inhibiting effect.P-Coumaric Acid can also inhibit mixed-function oxidation
Enzymatic activity and ring phosphorus phthalein amine (CP) cause body cell and property cell mutation.
In addition, the precursor or intermediate of p-Coumaric Acid or many compounds with higher application value.For example, to perfume (or spice)
Beans acid can pass through oxidation, cyclization reaction synthesizing coumarin；P-Coumaric Acid is generated by degradation reaction to light yl benzoic acid；To perfume (or spice)
Beans acid is alternatively arranged as the intermediate of expectorant farrerol.Therefore, p-Coumaric Acid is widely used in food, chemical industry, pharmaceuticals industry.
Acute lymphoblastic leukemia (ALL) is that a kind of B system originating from lymphocyte or T system cell are abnormal in marrow
The malignant neoplastic disease of hyperplasia.Normal hematopoiesis function can be assembled in marrow and be inhibited to the initial cell of paraplasm, while
Extraperiosteal tissue, such as meninx, lymph node, sexual gland, liver can be invaded.China once carried out the investigation of leukaemia incidence, ALL
Disease incidence is about 0.67/10 ten thousand.National disease incidence is apparently higher than in oil field, contaminated area disease incidence.ALL childhood (0~9 years old) is
Onset peak can account for 70% of leukemia of children or more.ALL accounts for 20% or so of adult leukemia in adult.ALL and other
Leukaemia is the same, and the occurrence and development of leukaemia cell originate from hematopoietic progenitor cells or stem cell.Currently, for its cause of disease and hair
Interpretation of the cause, onset and process of an illness system is not yet fully apparent from, and main treatment method has:
1. inducer remission
Inducer remission is to be preferably minimized leukaemia cell with chemotherapeutics after medical diagnosis on disease, reaches complete incidence graph mesh
's.
2. consolidating and strengthening treatment
After complete incidence graph, still there is different degrees of residual leukemic cell, need further to be consolidated with chemotherapeutics,
Intensive treatment.
3. maintenance therapy
It is the component part treated after complete incidence graph, has been achieved for good result in children ALL.
4. hematopoietic stem cell transplantation
There is the patient of appropriate donor in adult, especially there is the patient of high risk behaviors to suggest that carrying out allogeneic does carefully
Born of the same parents' transplanting.
5. central nervous system
Any kind of ALL emphasizes the early prevention of central nervous system, mainly intrathecal injection chemotherapeutics.Especially
Positive intrathecal injection chemotherapeutics is answered making a definite diagnosis central nervous system leukemia patient, until examination of cerebrospinal fluid is normal.When necessary
Carry out head radiotherapy.
People's acute lymphoblastic leukemia and tumour, cancer and chronic leukemia have relatively big difference, in treatment side
In the selection of formula, especially drug therapy, apparent difference is showed, the drug of chronic myelocytic leukemia is mainly for she at present
Imatinib, hydroxycarbamide, busulfan, homoharringtonine, cytarabine etc., the medicine owner of chronic lymphocytic leukemia
It wants are as follows: Chlorambucil, fludarabine, bendamustine, cyclophosphamide etc.；Immunization therapy includes Rituximab and Allan list
It is anti-；Buddhist nun is replaced for the targeted drug of B-cell receptor signal path, including according to Shandong.But the drug of acute lymphoblastic leukemia
Predominantly chemotherapeutics, cooperation chemotherapy use, and there is no the drugs individually to work well to it.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of p-Coumaric Acids to treat the white blood of people's acute lymphoblastic in preparation
The purposes of medicine.
The contents of the present invention are a kind of purposes of p-Coumaric Acid in preparation treatment people's acute lymphoblastic leukemia drug.
The treatment people acute lymphoblastic leukemia drug further includes pharmaceutically acceptable salt, carrier or preparation.
The preparation is tablet, pulvis, pill or capsule.
In the salt, carrier or preparation, the content of p-Coumaric Acid is 0.05-10mg/g.If being made into capsule or tablet,
The daily amount of p-Coumaric Acid is 20mg-100mg.If being made into pill, the daily amount of p-Coumaric Acid is 40mg-
100mg。
The invention has the advantages that the prior art uses chemotherapeutic treatment people acute lymphoblastic leukemia, chemotherapy poison is secondary
Effect is big, is easily destroyed the health of patient, or even can deepen the death of patient.Targeted drug production is complicated, and price is high, and curative effect is not
Stablize.The drug that the present invention provides a kind of based on coumaric acid, the drug is widely distributed in plant, as food at
Divide and is eaten for a long time by the mankind.Therefore, this drug has toxicity low, Small side effects, and selectivity is high, the advantages such as cheap.
Specific embodiment
Embodiment 1
Determine p-Coumaric Acid for malignant cell using a CCK8 kit (Dojindo, Kumamoto, Japan)
The cytotoxicity of strain.In terms of comprehensive, cell is divided the plate for filling up 96 holes, and each hole contains 5 × 104A malignant tumour
Cell improves nutrient using 100uL culture solution, instills and determines that the p-Coumaric Acid of metering observes 48 hours.10 holes μ L/ are added
Continue to observe 2 hours in the incubator after CCK-8 reagent.Finally, using micropore read equipment (ELX800, Bio TEK,
USA absorbing state) is observed at 450nm.All experiments will be repeated three times after same one formula trisection of experimental raw.It is right
It is as follows using the calculating of 5 software of GraphPad Prism in the value of the maximum 503nhibiting concentration IC50 of each cell strain system:
IC50 value of the p-Coumaric Acid for malignocytoma
From experimental result as can be seen that p-Coumaric Acid has malignant tumour certain inhibiting effect, investigating in range,
Optimal inhibiting effect is shown to people's acute lymphoblastic leukemia cell.
Claims (4)
1. a kind of p-Coumaric Acid is in the purposes of preparation treatment people's acute lymphoblastic leukemia drug.
2. purposes as described in claim 1, characterized in that the treatment people acute lymphoblastic leukemia drug further includes medicine
Acceptable salt, carrier or preparation on.
3. purposes as claimed in claim 2, characterized in that the preparation is tablet, pulvis, pill or capsule.
4. purposes as claimed in claim 2 or claim 3, characterized in that in the salt, carrier or preparation, the concentration of p-Coumaric Acid is
0.05-10mg/g。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811515930.5A CN109260188B (en) | 2018-12-11 | 2018-12-11 | Application of p-coumaric acid in preparation of medicine for treating human acute lymphocytic leukemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811515930.5A CN109260188B (en) | 2018-12-11 | 2018-12-11 | Application of p-coumaric acid in preparation of medicine for treating human acute lymphocytic leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109260188A true CN109260188A (en) | 2019-01-25 |
| CN109260188B CN109260188B (en) | 2021-01-01 |
Family
ID=65186921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811515930.5A Active CN109260188B (en) | 2018-12-11 | 2018-12-11 | Application of p-coumaric acid in preparation of medicine for treating human acute lymphocytic leukemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109260188B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075387A (en) * | 2016-06-26 | 2016-11-09 | 张伟强 | A kind of oral formulations treating chronic leukemia and preparation method thereof |
-
2018
- 2018-12-11 CN CN201811515930.5A patent/CN109260188B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106075387A (en) * | 2016-06-26 | 2016-11-09 | 张伟强 | A kind of oral formulations treating chronic leukemia and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 陈智 等: "《对香豆酸组合物对白血病细胞的增殖抑制作用及机制》", 《中国药学杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109260188B (en) | 2021-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101765575B1 (en) | Pharmaceutical composition for inhibiting a growth of cancer stem cells comprising aldehyde inhibitor and biguanide compounds | |
| CN103040804B (en) | Norwogonin and application thereof to preparation of medicines for treating acinetobacter baumannii infection | |
| Thye et al. | Malaysia’s breakthrough in Modern Actinobacteria (MOD-ACTINO) drug discovery research | |
| US20110021620A1 (en) | Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors | |
| CN101543499B (en) | Application of natural compound ursolic acid on antibiosis | |
| CN109260188A (en) | A kind of p-Coumaric Acid treats the purposes of people's acute lymphoblastic leukemia drug in preparation | |
| CN115531380A (en) | Application of fluoropyridoxine in preparation of anti-cancer drugs | |
| CN110038030A (en) | Anti- nasopharyngeal carcinoma active compound, chemotherapeutics and its application | |
| US9675563B2 (en) | Method for adjunctive treatment of cancer metastasis by using lycogen | |
| CN103027997A (en) | Chinese herbal compound for preventing and curing onset of disease of sturgeons due to infecting aeromonas hydrophila | |
| Houchens et al. | Effects of Corynebacterium parvum alone and in combination with adriamycin in experimental tumor systems | |
| CN106727535B (en) | A kind of anticancer pharmaceutical composition containing taxol | |
| CN112274537A (en) | Compound living insect soaking medicinal liquor of prevention/auxiliary medicine for treating cancer and preparation method and application thereof | |
| Soma et al. | In vivo analgesic, anti‐hyperglycaemic and CNS depressant studies of Commelina paludosa Blume | |
| CN110946862A (en) | Application of sanguinarine in inhibition of growth of multiple drug-resistant enterobacter hopcalis | |
| CN110812353A (en) | Application of genkwanin in preparation of drug for resisting listeria monocytogenes infection | |
| CN105517558A (en) | Filipendula vulgaris extract and uses thereof | |
| CN110150486A (en) | A kind of feed addictive for preventing and treating the intestines problems such as milking sow constipation diarrhea | |
| CN103083290B (en) | Application of trichoderma acid in preparation of antifungal medicines | |
| CN106983771B (en) | Medicine and composition for preventing and treating hippocampus head ulceration | |
| CN106668061B (en) | A kind of anticancer pharmaceutical composition containing cis-platinum | |
| Kumar et al. | In vitro inhibitory effects of Mucuna pruriens and Vetiveria zizanoides on selected human bacterial pathogens | |
| CN114344273A (en) | A soft capsule for treating tuberculosis and multi-drug resistant tuberculosis | |
| CN103191144B (en) | Medicine composition for treating cancers and application | |
| CN114558018A (en) | Application of gambogic acid and oxaliplatin in preparation of colorectal cancer treatment drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |